CAMBRIDGE, Mass.--(BUSINESS WIRE)--Visterra, Inc., developer of novel therapeutics to treat major infectious diseases, announced positive preclinical data showing that VIS410 demonstrated neutralization of H5N1 and H7N9 influenza strains that have pandemic potential. Developed using Visterra’s innovative antibody design technology, VIS410 is designed to be a broadly protective, fully human monoclonal antibody that targets a site on influenza hemagglutinin (HA) that is present across all influenza A subtypes and is resistant to mutation. These data were presented in a late-breaking oral session today at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Denver.
Help employers find you! Check out all the jobs and post your resume.
